Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.40 |
| ▸ | HTR2B | P41595 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905859 | 1.00 | HTR2C (0.40) | HTR2CHTR2BHTR2ACHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL4044871 | 0.99 | HTR2C (0.39) | HTR2CHTR2BHTR2ACHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL4044875 | 0.99 | HTR2C (0.39) | HTR2CHTR2BHTR2ACHRNB2CHRNA4 | |
| SCHEMBL4044164 | 0.82 | HTR2C (0.37) | HTR2CHTR2A | |
| SCHEMBL4044581 | 0.82 | HTR2C (0.37) | HTR2CHTR2A | |
| SCHEMBL4044132 | 0.81 | HTR2A (0.41) | HTR2CHTR2BHTR2AP2RX7 | |
| SCHEMBL4044135 | 0.81 | HTR2A (0.41) | HTR2CHTR2BHTR2AP2RX7 | |
| SCHEMBL905839 | 0.81 | HTR2C (0.38) | HTR2CHTR2BHTR2A | |
| SCHEMBL905838 | 0.81 | HTR2C (0.38) | HTR2CHTR2BHTR2A | |
| SCHEMBL4042851 | 0.80 | HTR2C (0.37) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | claimed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | claimed |
| EP-1370561-A2 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-17 | — | — | EP | claimed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| EP-1370561-A2 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2B 10/4885HTR2A 6/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2B 10/4885HTR2A 6/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2B 10/4885HTR2A 6/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | HTR2C 158/4885HTR2B 366/4885HTR2A 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.